Wells Fargo
ANTX icon

Wells Fargo’s AN2 Therapeutics ANTX Stock Holding History

Wells Fargo’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-128
Closed -$416 – 6892
2024
Q1 		$416 Buy
128
+2
+2% +$22 ﹤0.01% 6319
2023
Q4 		$2.58K Buy
126
+64
+103% +$1.07K ﹤0.01% 6058
2023
Q3 		$997 Buy
62
+27
+77% +$306 ﹤0.01% 6202
2023
Q2 		$298 Sell
35
-1,931
-98% -$13.9K ﹤0.01% 6583
2023
Q1 		$19.4K Buy
+1,966
New +$21.9K ﹤0.01% 5650
2022
Q4 		– Sell
-27
Closed – – 7447
2022
Q3 		$0 Sell
27
-46
-63% -$536 ﹤0.01% 6616
2022
Q2 		$1K Buy
+73
New +$967 ﹤0.01% 6453

Other funds holding ANTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo's ANTX Position: Q2 2024 in Review

Wells Fargo sold out of AN2 Therapeutics (ANTX) in Q2 2024, closing a stake of 128 shares — an estimated $416 sold.

Wells Fargo first reported a position in ANTX in Q2 2022 and held it in 7 quarters. The position peaked at $19.4K in Q1 2023. 45 funds tracked by Wall St. Rank hold ANTX as of Q2 2024.

  • Wells Fargo reported no remaining AN2 Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 128 AN2 Therapeutics shares in Q2 2024, an estimated $416.
  • Wells Fargo first reported a position in AN2 Therapeutics in Q2 2022 and held it in 7 quarters.
  • Wells Fargo's AN2 Therapeutics position peaked at $19.4K in Q1 2023.
  • 45 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.